Results 231 to 240 of about 65,592 (243)

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

New England Journal of Medicine, 2017
Jedd D Wolchok, Piotr Rutkowski, Jean-Jacques Grob   +2 more
exaly  

Ipilimumab

Reactions Weekly, 2022
openaire   +1 more source

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

New England Journal of Medicine, 2018
Robert J Motzer, Nizar M Tannir, David F Mcdermott   +2 more
exaly  

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New England Journal of Medicine, 2010
F Stephen Hodi, Caroline Robert, Dirk Schadendorf   +2 more
exaly  

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

New England Journal of Medicine, 2019
James Larkin, Jean-Jacques Grob, Piotr Rutkowski   +2 more
exaly  

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

New England Journal of Medicine, 2015
Michael A Postow, Anna C Pavlick, Caroline Robert   +2 more
exaly  

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

New England Journal of Medicine, 2015
James Larkin, Jean Jacques Grob, Dirk Schadendorf   +2 more
exaly  

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

New England Journal of Medicine, 2011
Caroline Robert, Luc Thomas, Igor N Bondarenko   +2 more
exaly  

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

New England Journal of Medicine, 2017
Jeffrey S Weber, Mario Mandala, Michele Del Vecchio   +2 more
exaly  

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Lancet, The
Elena Elez, Lars Henrik Jensen, Yann Touchefeu   +2 more
exaly